Hypertension in Patients with Cancer

被引:65
作者
de Souza, Vinicius Barbosa [1 ]
Silva, Eduardo Nani [1 ]
Ribeiro, Mario Luiz [1 ]
Martins, Wolney de Andrade [1 ]
机构
[1] Univ Fed Fluminense, Curso Posgrad Ciencias Cardiovasc, Niteroi, RJ, Brazil
关键词
Hypertension; Neoplasms; /; complications; Neoplasms / drug therapy; radiotherapy; Antihypertensive Agents; Indicators of Morbidity and Mortality; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TYROSINE KINASE INHIBITOR; BAROREFLEX FAILURE; SUNITINIB; BEVACIZUMAB; SORAFENIB; EFFICACY; PATHOGENESIS; MANAGEMENT; BIOMARKER;
D O I
10.5935/abc.20150011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a known association between chemotherapy and radiotherapy for treatment of cancer patients and development or worsening of hypertension. The aim of this article is to review this association. A literature search was conducted for articles reporting this association on the databases PubMed, SciELO and LILACS between 1993 and 2013. There was a high coprevalence of hypertension and cancer, since both diseases share the same risk factors, such as sedentary lifestyle, obesity, smoking, unhealthy diet and alcohol abuse. The use of chemotherapy and adjuvant drugs effective in the treatment of cancer increased the survival rate of these patients and, consequently, increased the incidence of hypertension. We described the association between the use of angiogenesis inhibitors (bevacizumab, sorafenib and sunitinib), corticosteroids, erythropoietin and non-steroidal anti-inflammatory drugs with the development of hypertension. We also described the relationship between hypertension and carotid baroreceptor injury secondary to cervical radiotherapy. Morbidity and mortality increased in patients with cancer and hypertension without proper antihypertensive treatment. We concluded that there is need for early diagnosis, effective monitoring and treatment strategies for hypertension in cancer patients in order to reduce cardiovascular morbidity and mortality.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 47 条
[1]  
[Anonymous], 2012, REV ERAS CARDIOL
[2]  
[Anonymous], MINERVA CARDIOANGIOL
[3]   The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer [J].
Bamias, A. ;
Manios, E. ;
Karadimou, A. ;
Michas, F. ;
Lainakis, G. ;
Constantinidis, C. ;
Deliveliotis, C. ;
Zakopoulos, N. ;
Dimopoulos, M. A. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (11) :1660-1668
[4]   Nonsteroidal Anti-Inflammatory Drugs: Cardiovascular, Cerebrovascular and Renal Effects [J].
Batlouni, Michel .
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2010, 94 (04) :556-563
[5]   Control of transcription by steroid hormones [J].
Beato, M ;
Truss, M ;
Chavez, S .
BASIS FOR CANCER MANAGEMENT, 1996, 784 :93-123
[6]   Experience with sorafenib and adverse event management [J].
Bellmunt, Joaquim ;
Eisen, Timothy ;
Fishman, Mayer ;
Quinn, David .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (01) :24-32
[7]   Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].
Burstein, Harold J. ;
Elias, Anthony D. ;
Rugo, Hope S. ;
Cobleigh, Melody A. ;
Wolff, Antonio C. ;
Eisenberg, Peter D. ;
Lehman, Mary ;
Adams, Bonne J. ;
Bello, Carlo L. ;
DePrimo, Samuel E. ;
Baum, Charles M. ;
Miller, Kathy D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816
[8]  
Calabrich AF, 2010, REV BRAS HEMATOL HEM, V32, P95
[9]   Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib [J].
Chu, Tammy F. ;
Rupnick, Maria A. ;
Kerkela, Risto ;
Dallabrida, Susan M. ;
Zurakowski, David ;
Nguyen, Lisa ;
Woulfe, Kathleen ;
Pravda, Elke ;
Cassiola, Flavia ;
Desai, Jayesh ;
George, Suzanne ;
Morgan, Jeffrey A. ;
Harris, David M. ;
Ismail, Nesreen S. ;
Chen, Jey-Hsin ;
Schoen, Frederick J. ;
Van den Abbeele, Annick D. ;
Demetri, George D. ;
Force, Thomas ;
Chen, Ming Hui .
LANCET, 2007, 370 (9604) :2011-2019
[10]  
Dalliago P, 1999, REV BRAS HIPERTENS, V6, P255